Alexion's Soliris price to be reviewed by Canadian regulator

7 February 2015

Canada’s Patented Medicine Prices review Board (PMPRB) will hold a public hearing in the matter of the price of the patented medicine Soliris (eculizumab), and USA-based Alexion Pharmaceuticals (Nasdaq: ALXN), the pharmaceutical company that holds the patent for Soliris and sells the drug in Canada. Further details on the public hearing and a case management conference will be announced at a later date.

Seen to be an unusual step by the PMPRB, the purpose of the hearing is to determine whether, under section 83 of the Patent Act, Alexion:

is selling or has sold the medicine known as Soliris in any market in Canada at a price that, in the Board’s opinion, is or was excessive; and
if so, what order, if any, should be made to remedy the excessive pricing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK